Predictive value of CHFR and MLH1 methylation in human gastric cancer
- 21 April 2014
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- Vol. 18 (2) , 280-287
Abstract
Background Gastric carcinoma (GC) has one of the highest mortality rates of cancer diseases and has a high incidence rate in China. Palliative chemotherapy is the main treatment for advanced gastric cancer. It is necessary to compare the effectiveness and toxicities of different regimens. This study explores the possibility of methylation of DNA damage repair genes serving as a prognostic and chemo-sensitive marker in human gastric cancer. Methods The methylation status of five DNA damage repair genes (CHFR, FANCF, MGMT, MLH1, and RASSF1A) was detected by nested methylation-specific PCR in 102 paraffin-embedded gastric cancer samples. Chi-square or Fisher’s exact tests were used to evaluate the association of methylation status and clinic-pathological factors. The Kaplan–Meier method and Cox proportional hazards models were employed to analyze the association of methylation status and chemo-sensitivity. Results The results indicate that CHFR, MLH1, RASSF1A, MGMT, and FANCF were methylated in 34.3 % (35/102), 21.6 % (22/102), 12.7 % (13/102), 9.8 % (10/102), and 0 % (0/102) of samples, respectively. No association was found between methylation of CHFR, MLH1, RASSF1A, MGMT, or FANCF with gender, age, tumor size, tumor differentiation, lymph node metastasis, and TNM stage. In docetaxel-treated gastric cancer patients, resistance to docetaxel was found in CHFR unmethylated patients by Cox proportional hazards model (HR 0.243, 95 % CI, 0.069–0.859, p = 0.028), and overall survival is longer in the CHFR methylated group compared with the CHFR unmethylated group (log-rank, p = 0.036). In oxaliplatin-treated gastric cancer patients, resistance to oxaliplatin was found in MLH1 methylated patients (HR 2.988, 95 % CI, 1.064–8.394, p = 0.038), and overall survival was longer in the MLH1 unmethylated group compared with the MLH1 methylated group (log-rank, p = 0.046). Conclusions CHFR is frequently methylated in human gastric cancer, and CHFR methylation may serve as a docetaxel-sensitive marker. MLH1 methylation was related to oxaliplatin resistance in gastric cancer patients.Keywords
This publication has 35 references indexed in Scilit:
- CHFR Suppression by Hypermethylation Sensitizes Endometrial Cancer Cells to PaclitaxelInternational Journal of Gynecological Cancer, 2011
- Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomasMolecular Cancer, 2009
- Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinomaWorld Journal of Gastroenterology, 2008
- The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancerJournal of Gastroenterology, 2006
- Circulating Tumor-Specific DNA: A Marker for Monitoring Efficacy of Adjuvant Therapy in Cancer PatientsCancer Research, 2005
- Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumorsNature Medicine, 2003
- Mitotic Checkpoint Protein hsMAD2 as a Marker Predicting Liver Metastasis of Human Gastric CancersJapanese Journal of Cancer Research, 2001
- Disruption of p53 in human cancer cells alters the responses to therapeutic agentsJournal of Clinical Investigation, 1999
- A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancerOncogene, 1999
- Frequent Microsatellite Instabilities and Analyses of the Related Genes in Familial Gastric CancersJapanese Journal of Cancer Research, 1996